Vijaya Diagnostic Centre Limited (VIJAYA)

Healthcare · Healthcare Services · NSE · Updated 22 July 2026

₹1,313.1 ↑ 29.54% (1Y)

🎯 Key Takeaways

Vijaya Diagnostic Centre Limited is in a growth phase driven by expanding diagnostic services and strategic leadership changes, though profitability metrics show signs of compression. The company has recently seen key executive appointments and departures, including the appointment of a new Company Secretary and the resignation of its CFO, signaling transitional leadership dynamics.
Revenue declined 7.6% QoQ to ₹169 in Q3FY25.
⚠️ 1) Margin compression in recent quarters despite stable OPM suggests rising operational costs or pricing pressures not yet mitigated. 2) Leadership tr

Market Cap

₹13,677

P/E Ratio

96.0

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About VIJAYA 📊 Interactive Charts

📖 The Story

Vijaya Diagnostic Centre Limited is in a growth phase driven by expanding diagnostic services and strategic leadership changes, though profitability metrics show signs of compression. The company has recently seen key executive appointments and departures, including the appointment of a new Company Secretary and the resignation of its CFO, signaling transitional leadership dynamics. Financial performance remains volatile quarter-on-quarter, with revenue growth flattening and operating margins under pressure despite stable top-line trends.

📰 What's Happening

In Q4 FY2026, the company released audited financial results and made the earnings call audio available to investors, enhancing transparency. A significant corporate action occurred on July 22, 2026, when 100,987 shares were allotted under the 2018 Employee Stock Option Plan, increasing paid-up capital and causing dilution. The CFO, Ankit Shah, resigned effective by July 24, 2026, citing personal reasons, with the company emphasizing a planned transition. Additionally, Ms. Naga Vasudha Tadepalli was appointed as Company Secretary and Compliance Officer on June 1, 2026, bringing over 16 years of regulatory experience to strengthen governance frameworks.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	121	121	139	133	155	156	183	169
Operating Profit	54	54	64	55	66	65	81	72
OPM %	40.6%	39.8%	41.3%	39.4%	40.7%	39.2%	41.5%	39.7%
Net Profit	28	26	34	26	34	32	42	35
EPS	₹2.69	₹2.57	₹3.26	₹2.53	₹3.27	₹3.06	₹4.09	₹3.42

Quarterly revenue has plateaued, declining from a peak of ₹183 crore in Q2FY25 to ₹169 crore in Q3FY25, while operating profit has dropped from ₹81 crore to ₹72 crore, leading to margin compression from 41.5% to 39.7%. Net profit and EPS also declined to ₹35 crore and ₹3.42 respectively in Q3FY25 from ₹42 crore and ₹4.09 in the prior quarter. Despite this, full-year trends show resilience in core operations, with OPM holding steady around 40% over multiple quarters. The financial trajectory reflects operational stabilization but limited growth momentum in the latest quarters.

🔮 Management Outlook & What's Next

Management has not provided explicit forward guidance in the reviewed filings, but the release of the Q4 FY2026 earnings call recording and formal disclosure of leadership transitions suggest efforts to maintain investor confidence. The company emphasized a smooth succession plan for the CFO role and highlighted the appointment of a seasoned compliance officer to reinforce governance. No official projections or strategic targets were disclosed in the available regulatory updates.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Healthcare Services

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Apollo Hospitals Enterprise Limited	1.16 L Cr	64.5	20.5%	21.9%	0.64
Max Healthcare Institute Limited	1.02 L Cr	101.2	—	—	—
Fortis Healthcare Limited	72,752	94.6	—	—	—
Aster DM Healthcare Limited	39,048	7.1	—	—	—
Narayana Hrudayalaya Ltd.	37,625	47.7	—	—	—
Global Health Limited	33,405	65.8	—	—	—
Krishna Institute of Medical Sciences Limited	30,477	80.3	—	—	—
Dr. Lal Path Labs Ltd.	26,871	63.6	—	—	—
Syngene International Limited	18,295	36.3	—	—	—
Dr. Agarwal's Health Care Limited	14,266	88.8	14.9%	6.8%	0.13

🔗 Peer Stock Analyses

APOLLOHOSP MAXHEALTH FORTIS ASTERDM NH

⚠️ Risk Factors

1) Margin compression in recent quarters despite stable OPM suggests rising operational costs or pricing pressures not yet mitigated. 2) Leadership transition in CFO role introduces execution risk in financial management during the handover period. 3) Flat revenue growth and declining profitability in key quarters raise concerns about scalability of the diagnostic business model. 4) Lack of forward guidance limits visibility into management's confidence in near-term performance recovery.

📋 Recent Filings

🧠 Analyst's Read

Vijaya Diagnostic Centre is navigating a transitional phase marked by leadership changes and margin pressure, despite stable revenue trends. Investors should monitor next quarter's financial performance and any updates on strategic initiatives or cost optimization efforts to assess the sustainability of profitability. The absence of guidance and rising competitive pressures in the diagnostic space warrant close attention.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on VIJAYA

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-22.

📡 Get AI alerts when VIJAYA files new disclosures

Track VIJAYA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track VIJAYA — Free

Free account · 2 AI queries/day